Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

NCT00065156 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
148
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Celgene